Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).
作者信息
Cesaro Simone, Mikulska Malgorzata, Hirsch Hans H, Styczynski Jan, Meylan Sylvain, Cordonnier Catherine, Navarro Davide, von Lilienfeld-Toal Marie, Mehra Varun, Marchesi Francesco, Besson Caroline, Masculano Raul Cordoba, Beutel Gernot, Einsele Herman, Maertens Johan, de la Camara Rafael, Ljungman Per, Pagano Livio
机构信息
Paediatric Haematology-Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
出版信息
Leukemia. 2023 Sep;37(9):1933-1938. doi: 10.1038/s41375-023-01938-5. Epub 2023 Jul 17.
Abstract
摘要
相似文献
1
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).来自2022年欧洲白血病感染会议（ECIL 9）的血液系统恶性肿瘤、造血干细胞移植和CAR-T治疗患者COVID-19管理建议更新
Leukemia. 2023 Sep;37(9):1933-1938. doi: 10.1038/s41375-023-01938-5. Epub 2023 Jul 17.
2
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia.成人血液恶性肿瘤和造血干细胞移植患者的分枝杆菌感染：第 8 届欧洲白血病感染会议指南。
Lancet Infect Dis. 2022 Dec;22(12):e359-e369. doi: 10.1016/S1473-3099(22)00227-4. Epub 2022 May 27.
3
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).2021 年欧洲白血病感染会议（ECIL 9）关于血液系统恶性肿瘤或造血细胞移植患者 COVID-19 管理的建议。
Leukemia. 2022 Jun;36(6):1467-1480. doi: 10.1038/s41375-022-01578-1. Epub 2022 Apr 29.
4
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).血液病患者和造血干细胞移植后巨细胞病毒感染管理指南，源自 2017 年白血病感染的欧洲会议（ECIL 7）。
Lancet Infect Dis. 2019 Aug;19(8):e260-e272. doi: 10.1016/S1473-3099(19)30107-0. Epub 2019 May 29.
5
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).血液恶性肿瘤患者和造血干细胞移植患者的病毒性肝炎管理：第 5 届欧洲白血病感染会议（ECIL-5）的建议。
Lancet Infect Dis. 2016 May;16(5):606-617. doi: 10.1016/S1473-3099(16)00118-3. Epub 2016 Apr 18.
6
Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.血液恶性肿瘤弥漫性血管内凝血的诊断与治疗进展。
Int J Hematol. 2021 Jan;113(1):34-44. doi: 10.1007/s12185-020-02992-w. Epub 2020 Sep 9.
7
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.联合策略优化嵌合抗原受体 T 细胞疗法在血液恶性肿瘤中的疗效。
Front Immunol. 2022 Aug 23;13:954235. doi: 10.3389/fimmu.2022.954235. eCollection 2022.
8
8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation.第八届欧洲白血病感染会议：2020 年儿童癌症或造血细胞移植后患者抗生素使用指南。
Lancet Oncol. 2021 Jun;22(6):e270-e280. doi: 10.1016/S1470-2045(20)30725-7. Epub 2021 Mar 31.
9
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.ECIL-6白血病和造血干细胞移植患者侵袭性念珠菌病、曲霉病和毛霉病治疗指南。
Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23.
10
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.癌症患者和接受 HSCT 或 CAR-T 治疗患者的 COVID-19 疫苗接种：免疫反应、真实世界疗效以及对未来的影响。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S55-S69. doi: 10.1093/infdis/jiad174.
引用本文的文献
1
Decoding Immunodeficiencies with Artificial Intelligence: A New Era of Precision Medicine.利用人工智能解码免疫缺陷：精准医学的新时代。
Biomedicines. 2025 Jul 28;13(8):1836. doi: 10.3390/biomedicines13081836.
2
Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19.COVID-19患者前瞻性队列中的恢复期血浆疗法与长期SARS-CoV-2抗病毒免疫反应
Curr Res Microb Sci. 2025 Jul 9;9:100440. doi: 10.1016/j.crmicr.2025.100440. eCollection 2025.
3
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10).来自欧洲白血病感染会议（ECIL - 10）的血液系统恶性肿瘤患者或接受细胞治疗患者新冠病毒病（COVID - 19）管理的大流行后建议
Leukemia. 2025 Jun 2. doi: 10.1038/s41375-025-02649-9.
4
COVID-19 Vaccination in Patients with Hematological Malignances.血液系统恶性肿瘤患者的新冠病毒疫苗接种
Vaccines (Basel). 2025 Apr 25;13(5):465. doi: 10.3390/vaccines13050465.
5
COVID-19 prior to hematopoietic stem cell transplantation increases the risk of acute graft-versus-host disease but does not affect overall mortality.造血干细胞移植前感染新型冠状病毒肺炎会增加急性移植物抗宿主病的风险，但不影响总体死亡率。
Bone Marrow Transplant. 2025 May;60(5):715-717. doi: 10.1038/s41409-025-02536-y. Epub 2025 Feb 21.
6
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.BNT162b2信使核糖核酸疫苗接种会影响滤泡性淋巴瘤和慢性淋巴细胞白血病患者的肠道微生物群组成。
Biomark Res. 2025 Feb 10;13(1):25. doi: 10.1186/s40364-025-00734-w.
7
[Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management].[新型冠状病毒肺炎管理正常化阶段的异基因造血干细胞移植]
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):977-981. doi: 10.3760/cma.j.cn121090-20240817-00308.
8
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.2023 - 2024年寒温带秋冬季节血液系统恶性肿瘤患者中的呼吸道病毒：EPICOVIDEHA - EPIFLUEHA报告
Am J Hematol. 2025 Mar;100(3):358-374. doi: 10.1002/ajh.27565. Epub 2024 Dec 23.
9
A Complex Case of COVID-19 Pneumonitis in a Patient With Follicular Lymphoma.1例滤泡性淋巴瘤患者的COVID-19肺炎复杂病例
Cureus. 2024 Nov 14;16(11):e73673. doi: 10.7759/cureus.73673. eCollection 2024 Nov.
10
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.与mRNA疫苗相比，ChAdOx1-S（AZD1222）疫苗接种后造血细胞移植受者体内的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体反应保留得更多。
Br J Haematol. 2024 Dec;205(6):2206-2218. doi: 10.1111/bjh.19874. Epub 2024 Nov 17.
本文引用的文献
1
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.接种疫苗的血液系统恶性肿瘤患者突破性 COVID-19：来自 EPICOVIDEHA 调查的结果。
Blood. 2022 Dec 29;140(26):2773-2787. doi: 10.1182/blood.2022017257.
2
Impact of SARS-CoV-2 Omicron on Rapid Antigen Testing Developed for Early-Pandemic SARS-CoV-2 Variants.奥密克戎变异株对早期流行的 SARS-CoV-2 变异株快速抗原检测的影响。
Microbiol Spectr. 2022 Aug 31;10(4):e0200622. doi: 10.1128/spectrum.02006-22. Epub 2022 Aug 9.
3
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer.癌症患者在第四次接种新冠病毒mRNA疫苗后抗体滴度升高且血清阴性率降低。
Cancer Cell. 2022 Aug 8;40(8):800-801. doi: 10.1016/j.ccell.2022.06.012. Epub 2022 Jul 1.
4
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.COVID-19 疫苗加强针在血液系统恶性肿瘤和实体瘤患者中的应用：一项系统评价和个体化患者数据荟萃分析。
Eur J Cancer. 2022 Sep;172:65-75. doi: 10.1016/j.ejca.2022.05.029. Epub 2022 Jun 3.
5
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.帕克洛维德降低高危患者的严重 2019 冠状病毒病和死亡率的有效性。
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.
6
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).2021 年欧洲白血病感染会议（ECIL 9）关于血液系统恶性肿瘤或造血细胞移植患者 COVID-19 管理的建议。
Leukemia. 2022 Jun;36(6):1467-1480. doi: 10.1038/s41375-022-01578-1. Epub 2022 Apr 29.
7
Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.长期异基因 HSCT 幸存者接种疫苗后，SARS-CoV-2 T 细胞反应缺失转化为减弱的体液免疫。
Blood Adv. 2022 May 10;6(9):2723-2730. doi: 10.1182/bloodadvances.2021006937.
8
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?SARS-CoV-2 免疫：我们了解多少，我们是否应该进行检测？
J Clin Microbiol. 2022 Jun 15;60(6):e0048221. doi: 10.1128/jcm.00482-21. Epub 2022 Mar 7.
9
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
10
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
Zotero 插件